

Company Announcement

Copenhagen, Denmark; December 15, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have given Genmab A/S (Nasdaq Copenhagen: GEN) power of attorney on their behalf to publish and report their trading in Genmab shares and related instruments, as follows:

1.	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	Mats Pettersson		
2.	Reason for the notification			
a)	Position/status	Chairman of the Board of Dire	ectors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s): section to be repeated for			
	(i) each type of instrument; (ii) each type of transaction;			
	(iii) each date; and (iv) each p	iv) each place where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	786	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Anders Gersel Pedersen		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Direct	etors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (ii) each type of transaction;		
	(iii) each date; and (iv) each p	place where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	589	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Dan Bruno		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Direct	etors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	-		
	(i) each type of instrument; (i	i) each type of transaction;		
	. , , , , ,	place where transactions have been conducted		
(a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock I	Jnits (partly as employee of	
		Genmab US, Inc., partly as be		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	1,091 (as employee)	
		DKK 0.00	393 (as board member)	
d)	Aggregated information			
	- Aggregated volume	1,484		
	- Price	DKK 0.00		
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Pernille Erenbjerg		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Direct	ctors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (i) each type of transaction;		
	(iii) each date; and (iv) each p	lace where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	to shares of Genmab A/S	
	instrument, type of instrument			
		D. (
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	393	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /				
	person closely associated				
a)	Name	Rick Hibbert			
2.	Reason for the notification				
a)	Position/status	Member of the Board of Direct	Member of the Board of Directors		
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emissi	on allowance market partic	ipant,		
	auction platform, auctioneer	or auction monitor			
a)	Name	Genmab A/S			
b)	LEI-code	N/A			
4.	Details of the transaction(s):	-			
	(i) each type of instrument; (i	i) each type of transaction;			
	(iii) each date; and (iv) each p				
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S		
	instrument, type of instrument				
	Identification code	DK0010272202			
b)			lists (south as a south as a f		
b)	Nature of the transaction	Grant of Restricted Stock of Genmab B.V., partly as board	Units (partly as employee of		
c)	Drice(a) and volume(a)		,		
	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 0.00	65 (as employee)		
۵/	A	DKK 0.00	393 (as board member)		
d)	Aggregated information	450			
	- Aggregated volume	458			
-0/	- Price	DKK 0.00			
e)	Date of the transaction	2016-12-15			
f)	Place of the transaction	Outside the market			

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /				
	person closely associated				
a)	Name	Peter Storm Kristensen			
2.	Reason for the notification				
a)	Position/status	Member of the Board of Direct	Member of the Board of Directors		
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emissi-	on allowance market partic	ipant,		
	auction platform, auctioneer	or auction monitor			
a)	Name	Genmab A/S			
b)	LEI-code	N/A			
4.	Details of the transaction(s):	section to be repeated for			
		each type of instrument; (ii) each type of transaction;			
	(iii) each date; and (iv) each p	place where transactions have been conducted			
a)	Description of the financial	Restricted Stock Units related to shares of Genmab A/S			
	instrument, type of instrument				
	Identification code	DK0010272202			
b)	Nature of the transaction		Jnits (partly as employee of		
		Genmab A/S, partly as board			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 0.00	115 (as employee)		
		DKK 0.00	393 (as board member)		
d)	Aggregated information				
	- Aggregated volume	508			
	- Price	DKK 0.00			
e)	Date of the transaction	2016-12-15			
f)	Place of the transaction	Outside the market	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Burton G. Malkiel		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Direct	ctors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi-	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (i) each type of transaction;		
	(iii) each date; and (iv) each p	place where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	393	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Paolo Paoletti		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Direct	ctors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (i) each type of transaction;		
	(iii) each date; and (iv) each p	lace where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	393	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	Jan G. J. van de Winkel		
2.	Reason for the notification			
a)	Position/status	President & Chief Executive (President & Chief Executive Officer	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (ii	each type of transaction;		
	(iii) each date; and (iv) each p	place where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Liberton de la companya del companya del companya de la companya d	DI40040070000		
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	5,819	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	David A. Eatwell		
2.	Reason for the notification			
a)	Position/status	Executive Vice President & C	Executive Vice President & Chief Financial Officer	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (ii	each type of transaction;		
	(iii) each date; and (iv) each p	lace where transactions have been conducted		
a)	Description of the financial	Restricted Stock Units related	I to shares of Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of Restricted Stock Uni	ts	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	3,634	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /				
	person closely associated				
a)	Name	Jan G. J. van de Winkel			
2.	Reason for the notification				
a)	Position/status	President & Chief Executive (President & Chief Executive Officer		
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emissi	on allowance market partic	ipant,		
	auction platform, auctioneer	or auction monitor			
a)	Name	Genmab A/S	Genmab A/S		
b)	LEI-code	N/A			
4.	Details of the transaction(s):	section to be repeated for			
	(i) each type of instrument; (i) each type of transaction;			
	(iii) each date; and (iv) each p	place where transactions have been conducted			
a)	Description of the financial	Warrants related to shares of	Genmab A/S		
	instrument, type of instrument				
	· ·				
	Identification code	DK0010272202			
b)	Identification code Nature of the transaction	DK0010272202 Grant of warrants			
b) c)			Volume(s)		
<u> </u>	Nature of the transaction	Grant of warrants	Volume(s) 17,941		
<u> </u>	Nature of the transaction	Grant of warrants Price(s)	` '		
c)	Nature of the transaction Price(s) and volume(s)	Grant of warrants Price(s)	` '		
c)	Nature of the transaction Price(s) and volume(s) Aggregated information	Grant of warrants Price(s)	` '		
c)	Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume	Grant of warrants Price(s)	` '		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /			
	person closely associated			
a)	Name	David A. Eatwell		
2.	Reason for the notification			
a)	Position/status	Executive Vice President & C	Executive Vice President & Chief Financial Officer	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emissi	on allowance market partic	ipant,	
	auction platform, auctioneer	or auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	N/A		
4.	Details of the transaction(s):	section to be repeated for		
	(i) each type of instrument; (i) each type of transaction;		
	(iii) each date; and (iv) each p	lace where transactions have been conducted		
a)	Description of the financial	Warrants related to shares of	Genmab A/S	
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Grant of warrants		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	11,202	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2016-12-15		
f)	Place of the transaction	Outside the market		

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /				
	person closely associated				
a)	Name	Dan Bruno			
2.	Reason for the notification				
a)	Position/status	Member of the Board of Directors			
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	Genmab A/S			
b)	LEI-code	N/A			
4.	Details of the transaction(s): section to be repeated for				
	(i) each type of instrument; (i	i) each type of transaction;			
	(iii) each date; and (iv) each p	lace where transactions have been conducted			
a)	Description of the financial	Warrants related to shares of Genmab A/S			
	instrument, type of instrument				
	Identification code	DK0010272202			
b)	Nature of the transaction	Grant of warrants (as employee of Genmab US, Inc., not as			
		board member)			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 0.00	3,363		
d)	Aggregated information				
	- Aggregated volume				
	- Price				
e)	Date of the transaction	2016-12-15			
f)	Place of the transaction	Outside the market			

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /					
	person closely associated					
a)	Name	Rick Hibbert				
2.	Reason for the notification					
a)	Position/status	Member of the Board of Directors				
b)	Initial notification/Amendment	Initial notification				
3.	Details of the issuer, emissi	of the issuer, emission allowance market participant,				
	auction platform, auctioneer	r or auction monitor				
a)	Name	Genmab A/S				
b)	LEI-code	N/A				
4.	Details of the transaction(s): section to be repeated for					
	(i) each type of instrument; (i					
	(iii) each date; and (iv) each p	place where transactions have been conducted				
a)	Description of the financial	Warrants related to shares of Genmab A/S				
	instrument, type of instrument					
		B1/00/1007000				
- 1 \	Identification code	DK0010272202				
b)	Nature of the transaction	Grant of warrants (as employee of Genmab B.V., not as board member)				
c)	Price(s) and volume(s)	Price(s)	Volume(s)			
		DKK 0.00	200			
d)	Aggregated information					
	- Aggregated volume					
	- Price					
e)	Date of the transaction	2016-12-15				
f)	Place of the transaction	Outside the market				

Tel: +45 7020 2728

Fax: +45 7020 2729



1.	Details of the person discharging managerial responsibilities /				
	person closely associated				
a)	Name	Peter Storm Kristensen			
2.	Reason for the notification				
a)	Position/status	Member of the Board of Directors			
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	Genmab A/S			
b)	LEI-code	N/A			
4.	Details of the transaction(s): section to be repeated for				
	(i) each type of instrument; (i				
	(iii) each date; and (iv) each p	place where transactions have been conducted			
a)	Description of the financial	Warrants related to shares of Genmab A/S			
	instrument, type of instrument				
	Identification code	DK0010272202			
b)	Nature of the transaction	Grant of warrants (as employee of Genmab A/S, not as board member)			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 0.00	354		
d)	Aggregated information				
	- Aggregated volume				
	- Price				
e)	Date of the transaction	2016-12-15			
f)	Place of the transaction	Outside the market			

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, non-Hodgkin's lymphoma and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

Tel: +45 7020 2728

Fax: +45 7020 2729



T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Tel: +45 7020 2728

Fax: +45 7020 2729